XML 91 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements - Astellas Agreements - Additional Information (Detail) - Astellas Agreement [Member] - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 35 Months Ended 45 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2010
Feb. 28, 2009
Feb. 28, 2009
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront, non-contingent and time-based payments received                     $ 360,100
Japan [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront, non-contingent and time-based payments received                     $ 40,100
Development and regulatory approval milestones   $ 117,500                  
Commercial sales milestone   $ 15,000                  
Additional consideration based on net sales description       Low 20% range              
Clinical development milestones             $ 12,500        
Milestones revenue     $ 10,000 $ 0 $ 10,000 $ 0          
Europe [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront, non-contingent and time-based payments received                   $ 320,000  
Development and regulatory approval milestones $ 425,000                    
Additional consideration based on net sales description       Low 20% range              
Clinical development milestones               $ 50,000 $ 40,000    
Milestones revenue       $ 0 $ 0 $ 0          
Percentage of joint development costs committed to fund 50.00%